What 23andMe's Bankruptcy Means for Your DNA Data

For years, 23andMe has been a leader in consumer genetic testing, providing millions of people with ancestry insights, health risks, and unknown familial connections. But the company’s financial troubles, potential bankruptcy, and looming sale have sparked a vital question: What happens to your DNA data now?

This situation raises serious concerns about data privacy, corporate responsibility, and the future of consumer DNA testing. Below, we dive into the causes of this crisis, the risks and benefits of a sale, and what users—and the industry—can do moving forward.

What Caused 23andMe’s Financial Crisis?

• Dwindling Sales: Market saturation reduced demand as the novelty wore off.
• Privacy Concerns: A 2023 data breach exposed millions of profiles, damaging trust.
• Regulatory Pressure: Increasing oversight raised compliance costs.
• Questionable Business Models: Heavy reliance on monetizing user data alienated customers.
• Costly Expansion: Attempts to pivot into drug development drained resources.

What Happens to Your DNA Data If 23andMe Is Sold?

The Big Question: If sold, who owns your genetic data?

• DNA data is a corporate asset that could transfer to new owners.
• Privacy policies may change, weakening current protections.
• Risk of misuse by insurers, employers, or third parties.
• Possible legal battles over ownership and consent.

What Can 23andMe Customers Do Right Now?

1. Download Your Raw DNA Data: Access your data while you still can.
2. Delete Your Account and Data: Request account deletion, though bankruptcy may limit effectiveness.
3. Monitor Sale Announcements: Watch who bids for the company and their intent.
4. Review Consent Agreements: Understand what rights you granted to 23andMe.

What Should 23andMe Do to Protect Customers?

• Transparent Communication: Notify users before any sale.
• Offer an Opt-Out: Allow users to withdraw their data from sale.
• Delete Unused Data: Purge inactive user data.
• Lobby for DNA Data Protections: Advocate for stronger genetic privacy laws.

The Positives: What Good Could Come From a Sale?

• New leadership could rebuild trust and strengthen the platform.
• Innovation opportunities in health tech and personalized medicine.
• Improved regulations could emerge, benefiting the entire industry.

The Negatives: Potential Dangers of the Sale

• Data monetization risk as new owners prioritize profits.
• Loss of trust in consumer DNA testing altogether.
• Potential discrimination if genetic data falls into the wrong hands.

How Can Users and Companies Prevent This in the Future?

For Users:

• Read the fine print and understand privacy policies.
• Choose services that give you control over your data.
• Support legislation like the Genetic Information Nondiscrimination Act (GINA).

For Companies:

• Build trust-first models with limited data use.
• Diversify revenue streams beyond selling data.
• Plan for worst-case scenarios with customer protections that survive bankruptcy.

Conclusion: DNA Data is the New Oil—Handle It with Care

The potential sale of 23andMe is a wake-up call. Your DNA contains your most personal information—health risks, ancestry, and more. Once shared, it cannot be changed or reset.

While new ownership might bring innovation, the risks of privacy loss and discrimination are real. Users must stay informed and vigilant, while companies must evolve with responsible data practices.

Your DNA is uniquely yours—make sure it stays that way.

Stay informed on tech, privacy, and AI trends at WhatIsAINow.com.